FDA Approves Abbott’s Pain Management Controller App
The smartphone-compatible app works with Abbott’s implantable neuromodulation technologies as part of its NeuroSphere Digital Care connected care management platform.
You may also be interested in...
The US FDA approved Abbott's system that allows physicians to communicate with patients and remotely program their neuromodulation device.
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
BIO Digital investment panel sees strong investment opportunities in telehealth, remote monitoring and converging digital products.